FT Options’s Sarepta Therapeutics SRPT Stock Holding History

FT Options’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$157K	Buy	24,300 +8,000	+49%	+$320K	0.24%	78
2017 Q2	$63K	Buy	16,300 +300	+2%	+$9.77K	0.11%	98
2017 Q1	$30K	Sell	16,000 -90,200	-85%	-$2.79M	0.04%	179
2016 Q4	$40K	Sell	106,200 -67,100	-39%	-$2.69M	0.05%	148
2016 Q3	$1.1M	Buy	173,300 +129,800	+298%	+$3.92M	0.87%	34
2016 Q2	$203K	Sell	43,500 -64,200	-60%	-$1.19M	0.17%	106
2016 Q1	$417K	Sell	107,700 -371,700	-78%	-$6.49M	0.44%	47
2015 Q4	$3.89M	Buy	+479,400	New	+$15.5M	2.87%	8

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

FT Options's SRPT Position: Q3 2017 in Review

FT Options reduced its Sarepta Therapeutics (SRPT) stake by 22% in Q3 2017, selling an estimated $139K and leaving 12,522 shares worth $568K. The position accounts for 0.86% of the portfolio, ranked #39.

FT Options first reported a position in SRPT in Q2 2016 and has held it in 6 quarters since. The position peaked at $3.01M in Q3 2016. 233 funds tracked by Wall St. Rank hold SRPT as of Q3 2017.

FT Options held 12,522 shares of Sarepta Therapeutics worth $568K as of Q3 2017.
FT Options sold 3,471 Sarepta Therapeutics shares in Q3 2017, an estimated $139K.
Sarepta Therapeutics made up 0.86% of FT Options's portfolio in Q3 2017, its #39 holding.
FT Options first reported a position in Sarepta Therapeutics in Q2 2016 and has held it in 6 quarters since.
FT Options's Sarepta Therapeutics position peaked at $3.01M in Q3 2016.
233 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.